These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35358872)

  • 1. Improvement of resistance to oxaliplatin by vorinostat in human colorectal cancer cells through inhibition of Nrf2 nuclear translocation.
    Tanaka S; Hosokawa M; Tatsumi A; Asaumi S; Imai R; Ogawara KI
    Biochem Biophys Res Commun; 2022 Jun; 607():9-14. PubMed ID: 35358872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
    Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
    Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98].
    Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):566-570. PubMed ID: 28534337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
    Wu YZ; Lin HY; Zhang Y; Chen WF
    J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
    Chian S; Li YY; Wang XJ; Tang XW
    Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
    Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
    Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
    Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.
    Wang XJ; Li Y; Luo L; Wang H; Chi Z; Xin A; Li X; Wu J; Tang X
    Free Radic Biol Med; 2014 May; 70():68-77. PubMed ID: 24556415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin F
    Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
    World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation.
    Nemoto S; Nakamura M; Osawa Y; Kono S; Itoh Y; Okano Y; Murate T; Hara A; Ueda H; Nozawa Y; Banno Y
    J Biol Chem; 2009 Apr; 284(16):10422-32. PubMed ID: 19240026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells.
    Tanaka S; Hosokawa M; Yonezawa T; Hayashi W; Ueda K; Iwakawa S
    Biol Pharm Bull; 2015; 38(3):435-40. PubMed ID: 25757925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of medicated serum prepared with Chinese herbal medicine Changweiqing on pharmacokinetics of oxaliplatin in colon cancer cells].
    Zhang Y; Sun XW; Xu JH; Lu H; Fan ZZ; Sun J; Zhang XX
    Zhong Xi Yi Jie He Xue Bao; 2012 Aug; 10(8):901-10. PubMed ID: 22883407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of nuclear factor (erythroid-derived 2)-like 2 protein level in the human colorectal adenocarcinoma cell line DLD-1 by a heterocyclic organobismuth(III) compound: Effect of organobismuth(III) compound on NRF2 signaling.
    Iuchi K; Tasaki Y; Shirai S; Hisatomi H
    Biomed Pharmacother; 2020 May; 125():109928. PubMed ID: 32004978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro exosomal transfer of Nrf2 led to the oxaliplatin resistance in human colorectal cancer LS174T cells.
    Mostafazadeh M; Kahroba H; Haiaty S; TazeKand AP; Samadi N; Rahbarghazi R; Nouri M
    Cell Biochem Funct; 2022 Jun; 40(4):391-402. PubMed ID: 35474580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells.
    Eades G; Yang M; Yao Y; Zhang Y; Zhou Q
    J Biol Chem; 2011 Nov; 286(47):40725-33. PubMed ID: 21926171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
    Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
    Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy.
    Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
    Oncol Rep; 2016 Dec; 36(6):3682-3690. PubMed ID: 27779719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.
    Yu T; An Q; Cao XL; Yang H; Cui J; Li ZJ; Xiao G
    Life Sci; 2020 Nov; 260():118294. PubMed ID: 32818544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.
    Konstantinopoulos PA; Spentzos D; Fountzilas E; Francoeur N; Sanisetty S; Grammatikos AP; Hecht JL; Cannistra SA
    Cancer Res; 2011 Aug; 71(15):5081-9. PubMed ID: 21676886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol induces AMPK-dependent MDR1 inhibition in colorectal cancer HCT116/L-OHP cells by preventing activation of NF-κB signaling and suppressing cAMP-responsive element transcriptional activity.
    Wang Z; Zhang L; Ni Z; Sun J; Gao H; Cheng Z; Xu J; Yin P
    Tumour Biol; 2015 Dec; 36(12):9499-510. PubMed ID: 26124005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.